Metastatic Solid Tumor Clinical Trials in Portland, Oregon

4 studies are recruiting for metastatic solid tumor in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Oregon Health & Science University (OHSU), Portland, Oregon
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  2. First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

    This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Oregon Health & Science University, Portland, Oregon
    Locations
    36 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT05875168 on ClinicalTrials.gov

  3. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigative Site #121, Portland, Oregon
    Locations
    15 in total
    Run by
    MOMA Therapeutics

    See if you can join NCT06974110 on ClinicalTrials.gov

  4. Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

    This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Providence Cancer Institute, Portland, Oregon
    Locations
    5 in total
    Run by
    Ankyra Therapeutics, Inc

    See if you can join NCT06171750 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.